Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.[1]
Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half life and is administered once a month.[2]
On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.[3]
In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects.[4] Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab.[5]
In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis.[6] In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.[7] In January 2023 the medication entered phase IIb trials for obesity.[2]
Immune activation: Dostarlimab Other: Ibalizumab
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.12.166.128